A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

NCT05709444 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Disease

Interventions

DRUG: Bremelanotide
DRUG: RAAS inhibition therapy

Sponsor

Palatin Technologies, Inc